Table 2. Univariate and multivariate analysis of overall survival in the study population.
| Variables | Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | ||
| Clinical variables | |||||||
| Gender (female) | 0.648 | 0.353–1.190 | 0.162 | – | – | – | |
| Age | 1.013 | 0.985–1.043 | 0.357 | – | – | – | |
| Smoking status | 1.572 | 0.625–3.953 | 0.336 | – | – | – | |
| ECOG PS | 1.775 | 1.101–2.862 | 0.019 | 2.158 | 1.108–4.205 | 0.024 | |
| Weight loss | 1.429 | 0.695–2.938 | 0.331 | – | – | – | |
| Histology (non-adenocarcinoma) | 2.158 | 1.158–4.021 | 0.015 | 1.578 | 0.683–3.643 | 0.286 | |
| Number of metastases | 1.199 | 0.917–1.567 | 0.185 | – | – | – | |
| Extrathoracic metastasis | 2.600 | 1.480–4.567 | 0.001 | 2.932 | 1.287–6.681 | 0.010 | |
| Liver metastasis | 2.064 | 0.987–4.316 | 0.054 | – | – | – | |
| Bone metastasis | 2.137 | 1.197–3.816 | 0.010 | 0.821 | 0.311–2.170 | 0.697 | |
| Molecular variables | |||||||
| Total number of gene alterations | 1.154 | 1.034–1.288 | 0.010 | 1.056 | 0.895–1.245 | 0.518 | |
| KRAS alteration | 0.791 | 0.373–1.678 | 0.541 | – | – | – | |
| TP53 alteration | 1.606 | 1.220–2.115 | 0.001 | 2.512 | 1.208–5.224 | 0.014 | |
| STK11 alteration | 1.208 | 0.971–1.503 | 0.090 | – | – | – | |
| KRAS/STK11 co-mutation | 10.936 | 2.337–51.164 | 0.002 | NC | – | – | |
| STK11/TP53 co-mutation | 2.415 | 1.008–5.784 | 0.048 | 1.673 | 0.433–6.465 | 0.456 | |
| TP53/KRAS co-mutation | 0.890 | 0.215–3.681 | 0.872 | – | – | – | |
| KRAS/STK11/TP53 co-mutation | 17.609 | 3.777–82.089 | <0.001 | 19.834 | 3.242–121.326 | 0.001 | |
| FGFR alteration | 5.273 | 1.591–17.474 | 0.007 | 2.348 | 0.484–11.397 | 0.289 | |
Statistically significant P values are reported in italics. CI, confidence interval; HR, hazard ratio; NC, non-calculable.